Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments

References

• Rommens JM, Iannuzzi MC, Kerem BS, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989:245:1059–1065.
   Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [published erratum appears in Science. Science. 1989 Sep 29;245(4925):1066–1073.
   PubMed Web of Science ®Google Scholar
• Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–1080.
   PubMed Web of Science ®Google Scholar
• Sosnay PR, Castellani C, Corey M, et al. Evaluation of the disease liability of CFTR variants. Methods MolBiol. 2011;742:355–372.
   PubMedGoogle Scholar
• Fuller CM, Benos DJ. CFTR. Am J Physiology: Physiol. 1992;263:C267–C86.
   PubMed Web of Science ®Google Scholar
• Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev. 2002;54(11):1359–1371.
   PubMed Web of Science ®Google Scholar
• Brennan M-L, Schrijver I. Cystic fibrosis: a review of associated phenotypes, use of molecular diagnostic approaches, genetic characteristics, progress, and dilemmas. J Mol Diagn. 2016;18(1):3–14.
   PubMed Web of Science ®Google Scholar
• Collie JT, Massie RJ, Jones OA, et al. Sixty‐five years since the New York heat wave: advances in sweat testing for cystic fibrosis. Ped Pulm. 2014;49(2):106–117.
   PubMed Web of Science ®Google Scholar
• Egan M, Flotte T, Afione S, et al. Defective regulation of outwardly rectifying Cl− channels by protein kinase A corrected by insertion of CFTR. Nature. 1992;358(6387):581–584.
   PubMed Web of Science ®Google Scholar
• Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. New England J Med. 2015;372(4):351–362.
   PubMed Web of Science ®Google Scholar
• Flotte TR. Gene therapy for cystic fibrosis. Curr Opin Mol Ther. 1999;1(4):510–516.
   PubMedGoogle Scholar
• Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527–538.
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med. 2015 May 17.
   Web of Science ®Google Scholar
• Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160–1167.
   PubMed Web of Science ®Google Scholar
• Paul-Smith MC, Bell RV, Alton WE, et al. Gene therapy for cystic fibrosis: recent progress and current aims. Expert Opin Orphan Drugs. 2016;4(6):649–658.
   Web of Science ®Google Scholar
• Griesenbach U, Pytel KM, Alton EW. Cystic fibrosis gene therapy in the UK and elsewhere. Hum Gene Ther. 2015;26(5):266–275.
   PubMed Web of Science ®Google Scholar
• Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 2014;1:427–451.
   PubMed Web of Science ®Google Scholar
• Sanlioglu S, Monick MM, Luleci G, et al. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther. 2001;1(2):137–147.
   PubMedGoogle Scholar
• Boyle MP, Enke RA, Adams RJ, et al. In utero AAV-mediated gene transfer to rabbit pulmonary epithelium. Mol Ther. 2001;4(2):115–121.
   PubMed Web of Science ®Google Scholar
• Samulski R. Adeno-associated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev. 1993. 1:74–80
   PubMedGoogle Scholar
• Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. Embo J. 1992;11:5071–5078.
   PubMed Web of Science ®Google Scholar
• Weitzman MD, Fisher KJ, Wilson JM. Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol. 1996;70(3):1845–1854.
   PubMed Web of Science ®Google Scholar
• Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods. 2002;28(2):158–167.
   PubMed Web of Science ®Google Scholar
• Clement N, Knop DR, Byrne BJ. Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther. 2009;20(8):796–806.
   PubMed Web of Science ®Google Scholar
• Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72(11):8568–8577.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Afione SA, Conrad C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA. 1993;90(22):10613–10617.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Afione SA, Solow R, et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem. 1993;268(5):3781–3790.
   PubMed Web of Science ®Google Scholar
• Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 1996;3(8):658–668.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23–36.
   PubMed Web of Science ®Google Scholar
• Beck SE, Jones LA, Chesnut K, et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol. 1999;73(11):9446–9455.
   PubMed Web of Science ®Google Scholar
• Fischer AC, Beck SE, Smith CI, et al. Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther. 2003;8(6):918–926.
   PubMed Web of Science ®Google Scholar
• Beck SE, Laube BL, Barberena CI, et al. Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. MolTher. 2002;6(4):546–554.
   Google Scholar
• Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 1998;351(9117):1702–1703.
   PubMed Web of Science ®Google Scholar
• Wagner JA, Nepomuceno IB, Messner AH, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther. 2002;13(11):1349–1359.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther. 2003;14(11):1079–1088.
   PubMed Web of Science ®Google Scholar
• Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther. 2001;12(15):1907–1916.
   PubMed Web of Science ®Google Scholar
• Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest. 2004;125(2):509–521.
   PubMed Web of Science ®Google Scholar
• Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol. 2002;23(1):5–27.
   PubMed Web of Science ®Google Scholar
• Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007 Aug;18(8):726–732.
   PubMed Web of Science ®Google Scholar
• Berns KI, Muzyczka N. AAV: an overview of unanswered questions. Hum Gene Ther. 2017;28(4):308–313.
   PubMed Web of Science ®Google Scholar
• Duan D, Yue Y, Yan Z, et al. Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther. 1998;9(18):2761–2776.
   PubMed Web of Science ®Google Scholar
• Duan D, Yue Y, Yan Z, et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest. 2000;105(11):1573–1587.
   PubMed Web of Science ®Google Scholar
• Sirninger J, Muller C, Braag S, et al. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther. 2004;15(9):832–841.
   PubMed Web of Science ®Google Scholar
• Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78(12):6381–6388.
   PubMed Web of Science ®Google Scholar
• Fischer AC, Smith CI, Cebotaru L, et al. Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther. 2007;15(4):756–763.
   PubMed Web of Science ®Google Scholar
• Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA. 2006;103(35):12993–12998.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Fischer AC, Goetzmann J, et al. Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. MolTher. 2010;18(3):594–600.
   Google Scholar
• Lynch CM, Munson KL, Stephan TM, et al. Small synthetic promoter elements increase expression of the full-length CFTR cDNA in AAV vectors. Pediatrics Pulm Suppl. 1999;19:230.
   Google Scholar
• Zhang LN, Karp P, Gerard CJ, et al. Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. Mol Ther. 2004;10(6):990–1002.
   PubMed Web of Science ®Google Scholar
• Yan Z, Sun X, Feng Z, et al. Optimization of recombinant adeno-associated virus-mediated expression for large transgenes, using a synthetic promoter and tandem array enhancers. Hum Gene Ther. 2015 Jun;26(6):334–346.
   PubMed Web of Science ®Google Scholar
• Carroll TP, Morales MM, Fulmer SB, et al. Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J Biol Chem. 1995;270(20):11941–11946.
   PubMed Web of Science ®Google Scholar
• Cebotaru L, Guggino WB. Complement yourself: transcomplementation rescues partially folded mutant proteins. Biophys Rev. 2014;6(1):169–180.
   PubMedGoogle Scholar
• Ostedgaard LS, Meyerholz DK, Vermeer DW, et al. Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice. Proc Natl Acad Sci USA. 2011;108(7):2921–2926.
   PubMed Web of Science ®Google Scholar
• Mansfield S, Kole J, Puttaraju M, et al. Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Therapy. 2000;7(22):1885.
   PubMed Web of Science ®Google Scholar
• Mount SM. A catalogue of splice junction sequences. Nucleic Acids Res. 1982;10:459–472.
   PubMed Web of Science ®Google Scholar
• Liu X, Luo M, Zhang LN, et al. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther. 2005;16(9):1116–1123.
   PubMed Web of Science ®Google Scholar
• Song Y, Lou HH, Boyer JL, et al. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6. 2-mediated segmental trans-splicing. Hum Gene Ther. 2009;20(3):267–281.
   PubMed Web of Science ®Google Scholar
• Lai Y, Yue Y, Liu M, et al. Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors. Hum Gene Ther. 2006;17(10):1036–1042.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. FEBS J. 2014;281(23):5186–5193.
   PubMed Web of Science ®Google Scholar
• Hogan BL, Barkauskas CE, Chapman HA, et al. Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell. 2014;15(2):123–138.
   PubMed Web of Science ®Google Scholar
• Neuringer I, Randell SH. Lung stem cell update: promise and controversy. Monaldi Arch Chest Dis. 2016;65:1.
   Google Scholar
• Liu X, Luo M, Guo C, et al. Analysis of adeno-associated virus progenitor cell transduction in mouse lung. Mol Ther. 2009;17(2):285–293.
   PubMed Web of Science ®Google Scholar
• Afione SA, Wang J, Walsh S, et al. TR. Intervirology. 1999;42(4):213–220.
   PubMed Web of Science ®Google Scholar
• Corti M, Elder M, Falk D, et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev. 2014;1 14033–14040.
   Web of Science ®Google Scholar
• Goldberg JB, Pier GB. The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis. Trends Microbiol. 2000;8(11):514–520.
   PubMed Web of Science ®Google Scholar
• Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol. 2006 Feb;41(2):164–170.
   PubMed Web of Science ®Google Scholar
• Lai HC, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000 Mar 23;342(12):851–859.
   PubMed Web of Science ®Google Scholar
• Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J. 2004;23(1):146–158.
   PubMed Web of Science ®Google Scholar
• Sun X, Sui H, Fisher JT, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest. 2010;120(9):3149–3160.
   PubMed Web of Science ®Google Scholar
• Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science. 2008;321(5897):1837–1841.
   PubMed Web of Science ®Google Scholar